全文获取类型
收费全文 | 444856篇 |
免费 | 27659篇 |
国内免费 | 2953篇 |
专业分类
耳鼻咽喉 | 6040篇 |
儿科学 | 9658篇 |
妇产科学 | 11404篇 |
基础医学 | 61795篇 |
口腔科学 | 14356篇 |
临床医学 | 35130篇 |
内科学 | 94695篇 |
皮肤病学 | 10168篇 |
神经病学 | 33008篇 |
特种医学 | 15421篇 |
外国民族医学 | 82篇 |
外科学 | 69401篇 |
综合类 | 10235篇 |
现状与发展 | 1篇 |
一般理论 | 90篇 |
预防医学 | 23116篇 |
眼科学 | 10670篇 |
药学 | 35334篇 |
1篇 | |
中国医学 | 2437篇 |
肿瘤学 | 32426篇 |
出版年
2021年 | 3704篇 |
2019年 | 3883篇 |
2018年 | 6554篇 |
2017年 | 4645篇 |
2016年 | 4816篇 |
2015年 | 6027篇 |
2014年 | 7729篇 |
2013年 | 10337篇 |
2012年 | 15809篇 |
2011年 | 15830篇 |
2010年 | 8769篇 |
2009年 | 7755篇 |
2008年 | 14233篇 |
2007年 | 15237篇 |
2006年 | 15339篇 |
2005年 | 14112篇 |
2004年 | 13138篇 |
2003年 | 12448篇 |
2002年 | 11974篇 |
2001年 | 29679篇 |
2000年 | 30680篇 |
1999年 | 24579篇 |
1998年 | 5362篇 |
1997年 | 4389篇 |
1996年 | 3978篇 |
1995年 | 3618篇 |
1994年 | 3212篇 |
1993年 | 2944篇 |
1992年 | 16163篇 |
1991年 | 14918篇 |
1990年 | 14225篇 |
1989年 | 14031篇 |
1988年 | 12633篇 |
1987年 | 12110篇 |
1986年 | 11166篇 |
1985年 | 10393篇 |
1984年 | 7002篇 |
1983年 | 5658篇 |
1982年 | 2794篇 |
1981年 | 2291篇 |
1979年 | 5519篇 |
1978年 | 3384篇 |
1977年 | 3006篇 |
1975年 | 2664篇 |
1974年 | 3097篇 |
1973年 | 2892篇 |
1972年 | 2833篇 |
1971年 | 2785篇 |
1970年 | 2522篇 |
1969年 | 2556篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
3.
4.
5.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs. 相似文献
6.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
7.
8.
9.
10.